VLON Stock Price, Vallon Pharmaceuticals, . Quote, Chart

Market Summary

USD0.42+0.01

Market Closed

2.44%

VLON Stock Price

View Fullscreen

VLON RSI Chart

VLON Valuation

Market Cap

1.5M

Price/Earnings (Trailing)

-0.12

Price/Sales (Trailing)

15.48

Price/Free Cashflow

-0.17

VLON Price/Sales (Trailing)

VLON Profitability

Return on Equity

-456.54%

Return on Assets

-278.48%

Free Cashflow Yield

-587.06%

VLON Fundamentals

VLON Revenue

Revenue (TTM)

100.0K

VLON Earnings

Earnings (TTM)

-12.8M

Earnings Growth (Yr)

12.23%

Earnings Growth (Qtr)

5.84%

Breaking Down VLON Revenue

52 Week Range

0.45

(Low)(High)

Last 30 days

-21.1%

Last 90 days

-59.8%

Trailing 12 Months

-92.8%

How does VLON drawdown profile look like?

VLON Financial Health

Current Ratio

2.64

VLON Investor Care

Shares Dilution (1Y)

793.72%

Diluted EPS (TTM)

4.72

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2020	0	0	0	100.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Vallon Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 13, 2022	thorell marella	sold	-	-	-28,517	-
Jul 01, 2022	thorell marella	acquired	-	-	38,023	-
Jun 04, 2021	kelly leanne m.	bought	6,152	4.08	1,508	chief financial officer
Jun 03, 2021	kelly leanne m.	bought	4,394	4.05	1,085	chief financial officer
Jun 02, 2021	kelly leanne m.	bought	14,628	4.00	3,657	chief financial officer
May 26, 2021	payne joseph e	bought	30,600	4.5	6,800	-
May 25, 2021	payne joseph e	bought	41,195	3.85	10,700	-
Feb 12, 2021	ammer richard	acquired	301,203	6.4	47,063	-
Feb 12, 2021	salmon pharma gmbh	acquired	301,203	6.4	47,063	-
Feb 12, 2021	baker david charles	bought	8,000	8.00	1,000	chief executive officer

Are Funds Buying or Selling VLON?

Are funds buying VLON calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own VLON

No. of Funds

Unveiling Vallon Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 13, 2024	altium capital management lp	4.99%	1,269,210	SC 13G/A
May 03, 2023	altium capital management lp	9.99%	221,986	SC 13G
May 02, 2023	tep biotech, llc	6.93%	204,909	SC 13G
Apr 25, 2023	agro albert	5.82%	172,189	SC 13D
Apr 25, 2023	hertz walter marc	13.04%	385,510	SC 13D
Apr 25, 2023	chaturvedi vipin	5.82%	172,189	SC 13D
Feb 13, 2023	lind global fund ii lp	0.1%	7,500	SC 13G/A
Jan 30, 2023	bigger capital fund l p	-	0	SC 13G/A
Dec 27, 2022	markey john	-	0	SC 13G/A
Sep 29, 2022	markey john	8.1%	849,489	SC 13G

Recent SEC filings of Vallon Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
May 14, 2024	424B3	Prospectus Filed
May 14, 2024	424B3	Prospectus Filed
May 13, 2024	8-K	Current Report
May 10, 2024	S-3	S-3
May 10, 2024	10-Q	Quarterly Report
May 09, 2024	DEF 14A	DEF 14A
Apr 29, 2024	PRE 14A	PRE 14A
Apr 01, 2024	8-K	Current Report
Mar 28, 2024	424B3	Prospectus Filed
Mar 28, 2024	424B3	Prospectus Filed

Vallon Pharmaceuticals, Inc. News

Latest updates

Vallon Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)				(In Thousands)
Description	(%) Q/Q	2020Q4	2020Q3	2020Q2	2020Q1
Revenue	-	-	-	-	100
Operating Expenses	41.4%	1,461	1,033	1,135	1,258
S&GA Expenses	-40.2%	180	300	327	375
R&D Expenses	74.8%	1,282	733	808	883
Interest Expenses	654.2%	67.00	-12.00	-12.00	-2.00
Net Income	-40.6%	-1,469	-1,045	-1,147	-1,161

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet														(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4
Assets	55.2%	4,587	2,956	4,404	5,642	2,097	3,833	5,569	8,007	5,944	8,335	10,140	11,647	14,600	955
Current Assets	50.9%	4,428	2,934	4,367	5,592	-	312	5,569	7,838	5,757	96.00	9,916	11,404	14,338	674
Cash Equivalents	126.3%	4,091	1,808	3,488	4,799	1,665	9.00	104	9.00	2,543	90.00	5,884	10,460	12,980	109
Net PPE	-12.5%	7.00	8.00	9.00	9.00	-	4.00	-	-	-	3.00	-	-	1.00	2.00
Liabilities	-33.7%	1,789	2,697	2,177	1,604	2,066	2,008	2,110	4,341	2,584	2,517	1,411	1,794	2,573	2,409
Current Liabilities	-37.7%	1,680	2,697	2,177	1,604	-	1,994	2,110	4,322	2,538	2,445	1,313	1,671	2,427	2,225
Shareholder's Equity	980.3%	2,798	259	2,227	4,038	31.00	2,342	3,459	3,666	3,360	5,818	8,729	9,853	12,027	-
Retained Earnings	-6.0%	-33,420	-31,533	-29,529	-27,392	-31,322	-18,496	-27,343	-26,310	-24,537	-21,902	-18,806	-17,549	-15,237	-12,599
Additional Paid-In Capital	13.9%	36,218	31,792	31,756	31,430	31,353	16,871	30,802	29,978	27,903	27,722	27,536	27,402	27,264	11,145
Shares Outstanding	395.0%	3,196	646	422	2,956	449	-	12,733	851	6,813	6,813	6,450	6,265	-	-
Float	-	-	-	-	9,500	-	-	-	5,200	-	-	-	22,900	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																	(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1
Cashflow From Operations	60.4%	-2,203	-5,560	-1,311	-3.00	-2,116	-844	-125	2,174	-2,290	-1,583	-1,289	-2,492	-2,948	-808	-1,064	-1,068	-766
Share Based Compensation	2.8%	37.00	36.00	326	-59.00	85.00	25.00	-	-181	181	186	134	138	168	39.00	52.00	28.00	35.00
Cashflow From Investing	-	-	-	-	-8.00	-	-3.00	-	-1,154	1,154	-576	-3,266	-	-	-	-	-	-2.00
Cashflow From Financing	15.6%	4,486	3,880	-	6,917	-	752	220	58.00	-23.00	-23.00	-21.00	-28.00	15,819	-7.00	-11.00	43.00	-29.00

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

VLON Income Statement

2024-03-31

Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Operating expenses:
Research and development	$ 933	$ 116
General and administrative	962	872
Total operating expenses	1,895	988
Loss from operations	(1,895)	(988)
Change in fair value of warrant liability	2	0
Interest income (expense), net	6	(1,162)
Net loss	$ (1,887)	$ (2,150)
Net loss per share of common stock, basic (in usd per share)	$ (0.46)	$ (15.04)
Net loss per share of common stock, diluted (in usd per share)	$ (0.46)	$ (15.04)
Weighted-average common shares outstanding, basic (in shares)	4,127,448	142,988
Weighted-average common shares outstanding, diluted (in shares)	4,127,448	142,988

VLON Balance Sheet

2024-03-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 4,091	$ 1,808
Prepaid expenses and other current assets	337	1,126
Total current assets	4,428	2,934
Property and equipment, net	7	8
Operating lease right-of-use assets	152	14
Total assets	4,587	2,956
Current liabilities:
Accounts payable	637	1,410
Accrued expenses	999	1,270
Warrant liability	1	3
Operating lease liabilities, current	43	14
Total current liabilities	1,680	2,697
Operating lease liabilities, non-current	109	0
Total liabilities	1,789	2,697
Commitments and contingencies (Note 11)
Stockholders' equity:
Common stock, $0.0001 par value; 250,000,000 shares authorized as of March 31, 2024 and December 31, 2023; 3,196,488 and 645,738 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in-capital	36,218	31,792
Accumulated deficit	(33,420)	(31,533)
Total stockholders’ equity	2,798	259
Total liabilities and stockholders' equity	$ 4,587	$ 2,956

About Vallon Pharmaceuticals, Inc.

0

WEBSITE	vallon-pharma.com

Vallon Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for Vallon Pharmaceuticals, Inc.? What does VLON stand for in stocks?

VLON is the stock ticker symbol of Vallon Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Vallon Pharmaceuticals, Inc. (VLON)?

As of Thu May 16 2024, market cap of Vallon Pharmaceuticals, Inc. is 1.55 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VLON stock?

You can check VLON's fair value in chart for subscribers.

What is the fair value of VLON stock?

You can check VLON's fair value in chart for subscribers. The fair value of Vallon Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Vallon Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VLON so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Vallon Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether VLON is over valued or under valued. Whether Vallon Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact Vallon Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VLON.

What is Vallon Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, VLON's PE ratio (Price to Earnings) is -0.12 and Price to Sales (PS) ratio is 15.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VLON PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Vallon Pharmaceuticals, Inc.'s stock?

In the past 10 years, Vallon Pharmaceuticals, Inc. has provided -0.361 (multiply by 100 for percentage) rate of return.